ASCO 2024 Plenary: LAURA Trial in Unresectable Stage III EGFRm NSCLC
Two Onc Docs
00:00
Navigating the Challenges of Osimertinib in NSCLC Treatment
This chapter examines the LAURA Trial's findings on osimertinib for patients with unresectable stage III EGFR-mutated non-small cell lung cancer. It covers the toxicity profile, the challenges of placebo control, and considerations for indefinite therapy amidst the absence of clear biomarkers.
Play episode from 07:57
Transcript
